Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Second-line Treatment Clear all
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery

NCT00015886
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, fluorouracil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
6
States / cities
Goldsboro, North Carolina • Greenville, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Jul 23, 2026, 2:50 AM EDT
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Interventions
Nemtabrutinib, Venetoclax, Rituximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
6
States / cities
Springdale, Arkansas • Long Beach, California • Pembroke Pines, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions
lisocabtagene maraleucel
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
59
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jul 23, 2026, 2:50 AM EDT
Withdrawn Phase 2 Interventional

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

NCT02967770
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Molecularly Tailored Second Line Therapy, Standard of Care Second Line Therapy
Other · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

NCT01289041
View directory record Official record
Conditions
Advanced Endometrial Cancer
Interventions
BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Morristown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Jul 23, 2026, 2:50 AM EDT
Terminated Phase 2Phase 3 Interventional

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

NCT01774578
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions
Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
Drug · Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jul 23, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

NCT01227018
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
STA-9090, Radiologic imaging, blood draw
Drug · Radiation · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Jul 23, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
150
States / cities
Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:50 AM EDT
Terminated Phase 1 Interventional

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003380
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

NCT01140347
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Placebo, Ramucirumab DP (IMC-1121B), BSC
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
18
States / cities
Orange, California • San Francisco, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

NCT01379534
View directory record Official record
Conditions
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
21
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 23, 2026, 2:50 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05273554
View directory record Official record
Conditions
Tumor, Adenocarcinoma
Interventions
Pembrolizumab, lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

NCT00059722
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ZD6474, Placebo, ZD1839
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
18
States / cities
Pine Bluff, Arkansas • Los Angeles, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

NCT01491672
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
RAD001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

NCT00493636
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Sorafenib, Placebo, Capecitabine
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 23, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

NCT01003938
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Topotecan, Erlotinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664
View directory record Official record
Conditions
Melanoma
Interventions
Anti-CD137 (4-1BB) (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

NCT00365053
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
belinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

NCT02499328
View directory record Official record
Conditions
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

NCT00054886
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
SU-011,248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Los Angeles, California • Mission Hills, California • Monterey Park, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 23, 2026, 2:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972
View directory record Official record
Conditions
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions
Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications, HER3-DXd
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

NCT03093870
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Varlitinib, Capecitabine, Placebo (for Varlitinib)
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
Not listed
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Gilbert, Arizona • Detroit, Michigan • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

NCT00696072
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dasatinib, Letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 23, 2026, 2:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

NCT00633594
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Rituximab, Bortezomib, Lenalidomide
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Terre Haute, Indiana • Chesterfield, Missouri • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jul 23, 2026, 2:50 AM EDT